<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation from HLA-matched allogeneic donors was used to treat two series of patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>No significant differences were detected in <z:hpo ids='HP_0000001'>all</z:hpo> comparisons made between the Registry series (38 patients) and the Seattle series (24 patients), and pooled data from the two series were used in the analyses </plain></SENT>
<SENT sid="2" pm="."><plain>Currently, 55% of the patients who received bone marrow transplants within three months of diagnosis are alive, but only 13% of the patients who received bone marrow transplants more than nine months after diagnosis are alive </plain></SENT>
<SENT sid="3" pm="."><plain>The difference between the two groups was significant (P less than .02) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients less than 21 years of age had a significantly higher survival rate than those patients who were 21 years or older at the time of transplantation (P less than .02) </plain></SENT>
<SENT sid="5" pm="."><plain>Survival rates were significantly higher for patients who had received 15 or fewer pretransplant transfusions than those who received more (P less than .05) </plain></SENT>
</text></document>